CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞免疫治疗相关噬血细胞性淋巴组织细胞增生症：与细胞因子释放综合征相比的发病机制、临床表现、诊断与管理（综述）
英文原题：Chimeric antigen receptor T cell immunotherapy‑associated hemophagocytic lymphohistiocytosis: Pathogenesis, clinical manifestation, diagnosis and management compared with cytokine release syndrome (Review).
查看英文原题
Chimeric antigen receptor T cell immunotherapy‑associated hemophagocytic lymphohistiocytosis: Pathogenesis, clinical manifestation, diagnosis and management compared with cytokine release syndrome (Review).
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法用于治疗血液系统恶性肿瘤，但存在危及生命的炎症性毒性风险，包括细胞因子释放综合征（CRS）和CAR-T 相关噬血细胞性淋巴组织细胞增多症（CARHLH）。CRS是CAR-T 细胞疗法的常见副作用，主要临床表现为发热和多器官功能损伤。CARHLH与CRS临床表现相似，但死亡率较高。CARHLH过去被认为是CRS的一种特定类型；然而，为及时启动治疗，必须尽早将其与CRS区分开来，因为两者管理方式不同。CARHLH与CRS的发病机制也不同。本综述旨在总结CARHLH的发病机制、诊断和治疗，以帮助其早期识别和管理。
展开英文摘要原文
Chimeric antigen receptor (CAR) T cell therapy is used to treat hematological malignancy.
However, it carries the risk of life threatening inflammatory toxicity, including cytokine release syndrome (CRS) and CAR T cell associated hemophagocytic lymphohistiocytosis (CARHLH). CRS is a common side effect of CAR T cell therapy, with fever and multiorgan functional impairment as the primary clinical manifestation. CARHLH and CRS have similar clinical manifestations.
However, CARHLH is associated with a high mortality rate. CARHLH was previously considered a specific type of CRS, however, it must be promptly differentiated from CRS for treatment initiation, with management differing from that of CRS. The pathogenesis of CARHLH differs from that of CRS. The present review aimed to summarize the pathogenesis, diagnosis and treatment of CARHLH to assist in its early identification and management.
论文信息
- 作者
- Hu J、Feng C、He L、Wang Y
- 单位
- Department of Hematology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, P.R. China.China
- 文献类型
- 综述
- 期刊
- Molecular medicine reports2025 Aug
- 原文标识
- PubMed 40417883 · DOI 10.3892/mmr.2025.13578
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →